Pentetate

Mechanism-of-action class: Plutonium Chelating Activity.

• Pentetate Indium Disodium In 111 is recommended for use in radionuclide cisternography.

• None known.contraindicated

Extreme care must be exercised to assure aseptic conditions in intrathecal injections. The maximum recommended intrathecal dose in the average patient (70 kg) is 18.5 MBq, 500 µ Ci. The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

The contents of the vial are radioactive. Adequate shielding of the preparation must be maintained at all times. Since the drug is excreted by the kidneys, caution should be exercised in patients with severely impaired renal function.

Aseptic meningitis and pyrogenic reactions have been rarely (less than 0.4%) observed following cisternography with Pentetate lndium Disodium In 111. One death has been reported to have occurred within 20 minutes following the administration of Pentetate Indium Disodium In 111 and appears to be drug related. In addition, two cases of septic meningitis have also been reported. There have also been reports of skin reactions and vomiting following administration of Pentetate lndium Disodium In 111. Relationship of the drug to these latter occurrences has not been established.

Pregnancy Category C Animal reproduction studies have not been conducted with GE Healthcare (Medi-Physics, Inc.) Indium DTPA In 111. Also, it is not known whether Pentetate Indium Disodium In 111 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Pentetate Indium Disodium In 111 should be given to a pregnant woman only if clearly needed. Ideally, examinations using radiopharmaceuticals, especially those elective in nature, of a woman of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses.

• Feb 18, 1982NDANDA017707Ge Healthcare
• Dec 29, 1989NDANDA018511Jubilant
• Mar 26, 2025ANDAANDA215146Curium

1. 1Drug Ineffective1452%
2. 2No Adverse Event1348%
3. 3Radioisotope Scan Abnormal311%
4. 4Dyspnoea27.4%
5. 5False Positive Investigation Result27.4%
6. 6Product Ineffective27.4%
7. 7Blood Pressure Increased13.7%
8. 8Cns Ventriculitis13.7%
9. 9Confusional State13.7%
10. 10Erythema13.7%
11. 11Feeling Hot13.7%
12. 12Foetal Heart Rate Deceleration Abnormality13.7%
13. 13Headache13.7%
14. 14Hypersensitivity13.7%
15. 15Incorrect Route Of Product Administration13.7%

Recent PubMed references pinned to Pentetate as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• [Fe-EOB-tCDTA] generates strong contrast in the blood but not in the liver, despite inhibiting cellular [Gd-EOB-DTPA](2-) uptake and partial liver excretion.
  European radiology experimental · 2026 · Ni F, Haeckel A, Hojjat H, et al.
  PMID 42126485DOI 10.1186/s41747-026-00731-0
• Multicentre prospective trial of abbreviated MRI using gadoxetic acid versus CT for detection of late recurrent HCC (AMRICT): study protocol.
  BMJ open · 2026 · Park HJ, Lee DH, Chang W, et al.
  PMID 42031482DOI 10.1136/bmjopen-2026-116809
• Development and preclinical evaluation of [(111)In]In-DTPA-EphA2-57-1: a single-photon emission computed tomography probe targeting EphA2-expressing tumors.
  Bioorganic & medicinal chemistry · 2026 · Sasaki M, Kimura H, Iwasawa T, et al.
  PMID 42025018DOI 10.1016/j.bmc.2026.118665
• Gadopentetate dimeglumine extravasation resulting in cutaneous ulceration: a case report.
  Journal of medical case reports · 2026 · Zhang W, Wang B, Kong X, et al.
  PMID 41987233DOI 10.1186/s13256-026-06017-8
• Gadoxetate-enhanced MRI Transitional Phase Parenchymal Signal: Effect on Washout and LI-RADS Diagnostic Performance for Hepatocellular Carcinoma.
  Radiology · 2026 · Cho SH, Jung YJ, Hong SB, et al.
  PMID 41914861DOI 10.1148/radiol.252892
• Whole-liver Palliative Radiotherapy Using SIB for Diffuse Liver Metastases: 3D-CRT versus (99m)Tc-GSA SPECT Image-guided VMAT.
  Anticancer research · 2026 · Shimohigashi Y, Toya R, Kai Y, et al.
  PMID 41895767DOI 10.21873/anticanres.18115
• Cerebral Accumulation of Gadolinium (Gd(3+)) and Related Cellular Stress Pathways in Rat Brain Tissue.
  Tomography (Ann Arbor, Mich.) · 2026 · Tuzcu G, Çildağ B, Çildağ S, et al.
  PMID 41893832DOI 10.3390/tomography12030037
• Prediction of progression of hepatic metastases from uveal melanoma using gadoxetic acid-enhanced magnetic resonance imaging.
  Melanoma research · 2026 · Lee JE, Lee S, Hwang JA, et al.
  PMID 41867001DOI 10.1097/CMR.0000000000001096

The 10 most recently updated of 282 ClinicalTrials.gov registrations naming Pentetate as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
  Recruiting · Phase 2 · Interventional · 60 enrolled · Children's Hospital Medical Center, Cincinnati
  NCT05501756updated 2026-06-12
• Efficacy of Temocillin Compared to Standard of Care in the Treatment of Neisseria Gonorrhoeae Infections
  Not yet recruiting · Phase 3 · Interventional · 360 enrolled · Assistance Publique - Hôpitaux de Paris
  NCT07631364updated 2026-06-08
• KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure
  Recruiting · Interventional · 124 enrolled · SterileCare Inc.
  NCT05879835updated 2026-06-04
• Regenerative Endodontics in Mature Necrotic Teeth
  Not yet recruiting · Interventional · 60 enrolled · Suez Canal University
  NCT07584928updated 2026-06-03
• A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women
  Not yet recruiting · Phase 3 · Interventional · 95 enrolled · GlaxoSmithKline
  NCT07596199updated 2026-05-19
• Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
  Not yet recruiting · Phase 1 · Interventional · 24 enrolled · National Cancer Institute (NCI)
  NCT06982222updated 2026-05-13
• Advanced Diffusion Imaging in Renal Cancer Patients
  Active not recruiting · Interventional · 39 enrolled · NYU Langone Health
  NCT06116253updated 2026-05-08
• Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion
  Recruiting · Interventional · 30 enrolled · Groupe Francais De Pneumo-Cancerologie
  NCT06247826updated 2026-04-29
• Clindamycin as an Alternative to Vancomycin in Patients Undergoing Aortic Cardiac Surgery With Extracorporeal Circulation (ECC)
  Recruiting · Phase 2 · Interventional · 25 enrolled · Nantes University Hospital
  NCT07267013updated 2026-04-28
• Biomarkers to Detect Endocrine Therapy Resistance
  Recruiting · Phase 2 · Interventional · 8 enrolled · University of Wisconsin, Madison
  NCT06067503updated 2026-04-13

Frequently asked questions

How does Pentetate work?

Mechanism-of-action class: Plutonium Chelating Activity.

What is Pentetate used for?

According to FDA labeling, Pentetate carries indications including: Pentetate Indium Disodium In 111 is recommended for use in radionuclide cisternography.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Pentetate?

Pentetate is classified as Plutonium Chelating Activity.

What are the contraindications for Pentetate?

Pentetate labeling lists contraindications including: None known.. Always consult the full prescribing information and a clinician.